ProKidney is a clinical-stage biotechnology company developing rilparencel (REACT), an autologous renal cell therapy intended to help preserve kidney function. The product is made from a patient’s own kidney cells and injected back into the kidney cortex. Development focuses on people with advanced chronic kidney disease, particularly when driven by diabetes, as an alternative path to slow decline toward dialysis.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0.2 | — | -16.7 | — |
| Q2 2025 | 0.2 | — | -16.6 | — |
| Q3 2025 | 0.2 | — | -16.5 | — |
| Q4 2025 | 0.2 | — | -19.2 | — |
| Q1 2026 | 0.2 | -1.7% | -20 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Independent Bank Corporation (IBCP), Fidus Investment Corporation (FDUS), Monopar Therapeutics Inc. (MNPR), Satellogic Inc. (SATL), Washington Trust Bancorp, Inc. (WASH), Alpha and Omega Semiconductor Limited (AOSL)